Alliance Wealth Advisors LLC UT Lowers Stock Position in Zoetis Inc. $ZTS

Alliance Wealth Advisors LLC UT trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 21.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,188 shares of the company’s stock after selling 4,430 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Zoetis were worth $2,369,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. North Star Asset Management Inc. raised its position in shares of Zoetis by 4.9% in the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after acquiring an additional 67 shares in the last quarter. CVA Family Office LLC grew its stake in Zoetis by 6.7% in the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after purchasing an additional 74 shares during the last quarter. Bank of Nova Scotia Trust Co. raised its holdings in Zoetis by 4.6% in the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after purchasing an additional 74 shares in the last quarter. RWA Wealth Partners LLC lifted its position in shares of Zoetis by 2.7% during the second quarter. RWA Wealth Partners LLC now owns 2,852 shares of the company’s stock valued at $445,000 after buying an additional 76 shares during the last quarter. Finally, Summit Place Financial Advisors LLC boosted its holdings in shares of Zoetis by 0.4% in the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after buying an additional 76 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 1.1%

Shares of Zoetis stock opened at $128.73 on Friday. The stock has a market cap of $54.34 billion, a PE ratio of 21.38, a price-to-earnings-growth ratio of 1.97 and a beta of 0.96. The firm has a fifty day moving average price of $125.41 and a 200 day moving average price of $134.72. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same period last year, the firm earned $1.40 EPS. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Barclays initiated coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Morgan Stanley set a $160.00 price target on shares of Zoetis in a report on Thursday, December 18th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. HSBC set a $140.00 target price on Zoetis in a research note on Wednesday, December 10th. Finally, Stifel Nicolaus lowered their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.